I. Introduction In our industry, not all companies are built for, or even aspire to, worldwide reach. Many are geographically limited, with commercial operations confined to a single country (such…
Remember me?Back in the mid-80s, when the Sony Walkman was a cassette player, companies like Upjohn, Parke-Davis, and Schering-Plough were well known in the pharmaceutical community. These names, and many others,…
The coverage of the announced negotiation by Sanofi to divest its European generics business triggered this cranky post. I don’t quite understand why so many journalists/analysts negatively criticize management when…
We're late to the this party, but HBM Partners issued their two annual reports on M&A Activity and New Drug Approvals. Both reports also have Excel files with raw…
The reports of my death have been greatly exaggerated. Mark Twain In July, we summarized the issue of companies acquiring other companies in tax-friendly countries. These so-called "inversions" were not…
Source: Nature Biotechnology, 32, 617–619, (2014), Published online 08 July 2014 Our good friends at Venture Valuation published an interesting study in the July issue of Nature Biotechnology. In…
Today we learn that Endo is acquiring Boca Pharmacal for $225 million: Boca Pharmacal is a specialty generics company that focuses on niche areas, commercializing and developing products…
We don't normally comment on stock activity, but the market response to the Perrigo Elan announcement caught our eye: As was pointed out in The Guardian: Perrigo, which…
Ok, we have to admit. This is not exactly a "how to" guide. In fact, writing such a guide may not be possible. But first, let's dispel the…
Biotech business development has become more sophisticated and more complex. Yet we see companies running processes which are suboptimal. Here is a case in point. We're reviewing several…